Cargando…

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States

Detalles Bibliográficos
Autores principales:	Murayama, Anju, Kamamoto, Sae, Saito, Hiroaki, Tanimoto, Tetsuya, Ozaki, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Medical Association 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169267/ https://www.ncbi.nlm.nih.gov/pubmed/37179719 http://dx.doi.org/10.31662/jmaj.2022-0210

Ejemplares similares

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020
por: Murayama, Anju, et al.
Publicado: (2022)

Trends in Industry Payments to Diabetologists and Endocrinologists in the United States During the COVID-19 Pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States
por: Murayama, Anju, et al.
Publicado: (2022)

Industry Payments During the COVID-19 Pandemic to Cardiologists in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
por: Murayama, Anju, et al.
Publicado: (2020)

Evaluation of Financial Conflicts of Interest and Quality of Evidence Underlying the American Diabetes Association Clinical Practice Guidelines: The Standards of Medical Care in Diabetes, 2021
por: Shigeta, Haruki, et al.
Publicado: (2023)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019
por: Kamamoto, Sae, et al.
Publicado: (2023)

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians
por: Murayama, Anju, et al.
Publicado: (2022)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
por: Hashimoto, Takanao, et al.
Publicado: (2022)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis
por: Ozaki, Akihiko, et al.
Publicado: (2019)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
por: Kosaka, Makoto, et al.
Publicado: (2023)

Woman Editors-in-Chief of English-Language Medical Journals Published by the Japanese Professional Medical Associations
por: Harada, Kayo, et al.
Publicado: (2021)

Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
por: Mamada, Hanano, et al.
Publicado: (2023)

Industry Payments to Nephrologists in the United States
por: Pakanati, Abhinandan R, et al.
Publicado: (2021)

COVID-19 infection during the Olympic and Paralympic Games Tokyo 2020
por: Yashio, Tomoki, et al.
Publicado: (2021)

An exploratory study comparing students' science identity perceptions derived from a hands‐on research and nonresearch‐based summer learning experience
por: Hernandez‐Matias, Liz, et al.
Publicado: (2019)

Optimizing High-risk Infant Follow-up in Nonresearch-based Paradigms: The New England Follow-up Network
por: Litt, Jonathan S., et al.
Publicado: (2020)

Will initial consultation patterns among undiagnosed cancer patients be the same after this COVID-19 pandemic? Experiences from the 2011 triple disaster in Fukushima, Japan
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Japan’s Drug Regulation Framework: Aiming for Better Health or Bigger Profits?
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Are the issues pointed out by ChatGPT can be applied to Japan? - Examining the reasons behind high COVID-19 excess deaths in Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

A few remarks on limits of research risks and research payments
por: Różyńska, Joanna
Publicado: (2022)

Comparing cancer drug approval systems in the United States and Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Is the Testing System No Longer Effective for Coronavirus Disease 2019? Elucidating the Policy Change in the United Kingdom
por: Kaneda, Yudai, et al.
Publicado: (2022)

Facial plating industry payments: An analysis of the open payments database
por: Lorenz, F. Jeffrey, et al.
Publicado: (2023)

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
por: Fabbri, Alice, et al.
Publicado: (2018)

Japan's COVID-19 response: underutilized beds and misused funds
por: Saito, Yoshika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_543qdh36gur74m55edgmkmm85r